Loading resource…

Department of Medicine, ASST Mantova, C. Poma Hospital, Italy
The article provides an in-depth review of the latest guidelines and evidence regarding heart failure management, emphasizing the shift from a sequential approach to a more integrated drug therapy strategy. It highlights the efficacy of new medications like vericiguat and omecamtiv mecarbil in treating heart failure with reduced ejection fraction (HFrEF). The authors analyze clinical trial data and discuss the implications for patient care and healthcare costs.
No account needed